An FDA official who recently resign is being sued by Aurinia Pharmaceuticals (AUPH) for allegedly soliciting a bribe and tanking its stock with false statements in a revenge campaign against a former colleague, Liz Essley Whyte of The Wall Street Journal reports. Dr. George Tidmarsh was hired in July to lead the agency’s drug division.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals (AUPH) Q3 Earnings Cheat Sheet
- Aurinia Pharmaceuticals Advances Voclosporin Study in Young Lupus Nephritis Patients
- Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients
- Aurinia Pharmaceuticals to Present New LUPKYNIS Data at Key Conferences
- Aurinia ‘stands behind’ favorable benefit/risk profile of LUPKYNIS